Fact Meets Function

This case report explores methylene blue as a potential treatment for post-cardiac arrest refractory shock, a condition with over 50% mortality and few evidence-based options. While methylene blue has shown promise in post-operative cardiac bypass settings, its use in cardiac arrest outside surgery remains largely unstudied. The case suggests methylene blue may warrant clinical investigation as a therapeutic option for practitioners managing critically ill post-arrest patients.

This PLoS One study demonstrates that methylene blue combined with vitamin B12 effectively alleviates experimental septic shock by modulating specific cellular pathways (KCNMB1 and cGMP-PRKG), addressing circulatory failure and microvascular dysfunction. The research validates a synergistic mechanism between two compounds often used separately in vasodilatory shock management. For practitioners, this finding supports the rationale for combined MB+VB12 protocols in critical care and suggests potential applications beyond sepsis in other conditions involving vascular dysfunction and metabolic dysregulation.

This real-world comparative effectiveness study evaluates methylene blue and high-dose hydroxocobalamin as adjunctive vasodilator therapies in septic shock patients when standard treatments fail. The research uses a large multicenter electronic health record network to compare hemodynamic outcomes between these two compounds. For practitioners using peptide and compound-based protocols, this data provides evidence on an emerging supportive therapy class that may complement standard sepsis management.

Methaemoglobin (MetHb) is an oxidised form of haemoglobin that cannot carry oxygen, caused by genetic mutations, enzyme deficiencies, or exposure to oxidising agents like dapsone and cocaine-derived anaesthetics. Symptoms emerge at MetHb concentrations above 10% and include cyanosis, confusion, arrhythmias, and potentially death, though arterial blood gas readings appear misleadingly normal. Intravenous methylene blue is the first-line treatment for symptomatic cases, with alternative therapies including high-dose vitamin C and exchange transfusion, though evidence for optimal use of alternatives remains limited.

This in vitro study demonstrates that methylene blue prevents LPS-induced microglial activation in rat cortical glial cultures by maintaining ramified morphology and reducing cell body enlargement. Methylene blue’s neuroprotective effect is attributed to Nrf2 pathway activation, which suppresses pro-inflammatory cytokine production and blocks the transition to activated microglial phenotype. The findings suggest methylene blue may have therapeutic potential in neuroinflammatory and neurodegenerative disease contexts. Unlike menadione, methylene blue showed no adverse effects when applied alone.